GSK broadens drug-development partnership with NPS

08/2/2011 | Reuters

GlaxoSmithKline expanded a collaboration with NPS Pharmaceuticals to take over development and marketing of ronacaleret. The drug was designed to treat osteoporosis, but GSK will develop it as stem cell transplant therapy. The agreement also grants NPS development rights to SB-423557 and SB-423562 for autosomal dominant hypocalcemia with hypercalciuria.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC